https://www.selleckchem.com/pr....oducts/recilisib.htm
Poly(ADP-ribose) polymerases inhibitor (PARPi) have shown clinical efficacy in ovarian carcinoma, especially in those harboring defects in homologous recombination (HR) repair, including and mutated tumors. There is increasing evidence however that PARPi resistance is common and develops through multiple mechanisms. ID8 F3 (HR proficient) and ID8 (HR deficient) murine ovarian cells resistant to olaparib, a PARPi, were generated through stepwise drug concentrations in vitro. Both sensitive and resistant cells lines were pharmacological
Like
Comment
Share
